Modality
ERT
MOA
FXIai
Target
BCMA
Pathway
Apoptosis
NB
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jun 2029
Phase 1Current
NCT05879648
385 pts·NB
2021-06→2029-06·Completed
NCT04669754
485 pts·NB
2018-02→2026-02·Recruiting
870 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-201mo agoInterim· NB
2029-06-123.2y awayInterim· NB
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Recruit…
P1
Complet…
Catalysts
Interim
2026-02-20 · 1mo ago
NB
Interim
2029-06-12 · 3.2y away
NB
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05879648 | Phase 1 | NB | Completed | 385 | ACR20 |
| NCT04669754 | Phase 1 | NB | Recruiting | 485 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| REG-2328 | Regeneron | Phase 1 | BCMA |